noninvasively evaluated the efficacy of mammography radiomics signatures in diagnosing the patients’ HER2 status with breast carcinoma, including mediolateral oblique (MLO) and cranial caudal (CC) views, with an AUC of 0.846 in the training set and an AUC of 0.74 in the testing set. This evidence concerns the gene ERBB2 and breast carcinoma.